Komodo Health

Overview

Komodo Health is a U.S. healthcare intelligence platform for real-world evidence, patient-journey analytics, trial planning, market access, commercial analytics, and medical-affairs workflow. Its current public packaging centers on three layers: Healthcare Map as the patient-data foundation, Marmot as the healthcare AI and methods layer, and Komodo Home as the user workflow environment.

For manufacturer buyers, Komodo is strongest when teams need software-enabled cohort building, patient finding, treatment-pathway analysis, site-selection analytics, and RWE / HEOR workflows without commissioning a bespoke consulting project for every question. Komodo describes Healthcare Map as spanning 1T+ linked records, 330M+ de-identified patient journeys, and 60+ sources refreshed daily; buyers should treat those scale claims as a starting point for cohort-level diligence, not as proof that every population or endpoint is covered equally.

Komodo should not be treated as a global evidence vendor, hub operator, CRM system of record, or oncology-specific EHR abstraction platform by default. Buyers should compare it against IQVIA, Flatiron, Tempus, Veeva Crossix, Definitive Healthcare, HealthVerity, and focused RWE platforms by data provenance, clinical depth, workflow usability, statistical transparency, auditability, and the split between self-service software and vendor-delivered services.

Real-World Evidence Capability Model

The framework below standardizes how Rx Almanac evaluates real-world-evidence capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Komodo Health is evaluated as a healthcare intelligence platform built around Healthcare Map, Marmot, and Komodo Home for RWE, patient-journey, trial, medical, access, and commercial analytics.

Capability	Buyer should compare	Komodo Health readout
Data assets and linkage coverage	Claims, EHR, registry, lab, mortality, genomic, provider, and patient-level linkage breadth.	Major coverage workflow. Healthcare Map is the main reason to evaluate Komodo; Komodo frames it as a 1T+ linked-record, 330M+ journey, 60+ source foundation. Validate cohort-level source coverage and partner dependencies.
Study design and causal inference	Protocol development, statistical methods, bias control, synthetic/external controls, and reproducibility.	Documented, validate methods. Komodo supports cohort building, patient-journey analysis, site selection, and evidence workflows, but buyers should inspect methods documentation before using outputs for high-stakes evidence packages.
Regulatory, HTA, and payer evidence packages	FDA, EMA, NICE/HTA, payer value dossiers, label expansion, and post-market evidence use cases.	Relevant but scope-dependent. CMS license and RWE use cases strengthen the platform, but buyers should separate exploratory analytics from submission-grade study packages and payer / HTA dossiers.
Oncology, rare disease, and specialty depth	Fit for small populations, biomarkers, longitudinal oncology records, rare-disease cohorts, and specialty-drug endpoints.	Strong breadth, variable depth. Komodo is useful for specialty and rare-disease journey analytics, while biomarker-, staging-, and chart-abstraction-heavy oncology work may require Flatiron, Tempus, or other specialty data partners.
Analytics platform and self-service workflow	User-facing software, cohort builders, query tools, dashboards, and analyst service model.	Major analytics workflow. Komodo Home, Marmot, MapLab, MapView, MapExplorer, and purpose-built apps make Komodo more workflow-oriented than a static data feed. Validate user permissions, audit trails, exports, and services support.
Privacy, governance, and refresh cadence	HIPAA controls, de-identification, data rights, governance, update frequency, and auditability.	Core diligence area. Confirm tokenization, linkage, permitted uses, data-source rights, refresh cadence, and downstream sharing restrictions for each use case.

Buyer Fit

• Buyer trigger: Include Komodo when the manufacturer needs U.S. patient-journey analytics, RWE / HEOR workflow, trial-site selection, patient finding, market-access analytics, or commercial measurement grounded in longitudinal healthcare data.
• Best-fit teams: HEOR, RWE, medical affairs, commercial analytics, market access, clinical development, data science, and launch teams that need repeatable cohort and journey analysis.
• Therapy and product fit: Strongest fit for specialty, oncology, rare disease, immunology / autoimmune, neurology, and infectious-disease questions where claims breadth and partner data can identify populations, treatment patterns, and care gaps.
• Where to be careful: Global studies, deep oncology biomarker work, regulatory submissions, rare cohorts with sparse data, and field-sales workflows that need simple rep-facing interfaces may require another vendor or a clearly scoped companion platform.
• Commercial fit: Subscription plus services models are likely; scope should define data products, permitted uses, named workflows, user groups, refresh cadence, export rights, and support model.
• Workflow diligence: Confirm source provenance, cohort completeness, linkage quality, data lag, self-service versus services scope, AI output review, and whether the same data can support evidence, access, clinical, and commercial users without governance conflict.

Differentiators

• Healthcare Map breadth: Komodo’s central advantage is the scale and linkage of longitudinal U.S. patient journeys across claims and partner-enriched data layers.
• Three-layer platform packaging: Healthcare Map, Marmot, and Komodo Home clarify whether the buyer is buying data foundation, AI-assisted methods, user workflow, or all three.
• Workflow-oriented analytics: Komodo Home, MapLab, MapView, MapExplorer, and adjacent applications make Komodo more actionable for operating teams than a raw data license alone.
• AI-assisted analytics posture: Marmot and related AI workflow work can accelerate cohort analysis and question-answering, but buyers should require transparent logic, review controls, and reproducible outputs.
• MapEnhance partner model: Clinico-genomic, lifestyle, socioeconomic, and other partner data can deepen claims-based analysis when the specific use case needs more clinical or contextual signal.
• Clinical development adjacency: Public peer-reviewed work with Janssen supports Komodo’s role in trial-site selection and patient-enrollment prediction.
• Commercial and medical affairs bridge: Iris, Pulse, Aperture, patient-insurance analytics, and publications-planning workflow give Komodo adjacency into field, market access, omnichannel, and medical-affairs use cases.

RFP Questions

• Which data sources are native to Komodo, separately licensed, partner-dependent, or unavailable for the target population?
• What evidence can Komodo provide for cohort completeness, match rates, linkage accuracy, data lag, and refresh cadence in the exact therapy area?
• How are Healthcare Map, Marmot, Komodo Home, MapLab, MapView, MapExplorer, Iris, Pulse, and Aperture licensed and governed across user groups?
• What parts of a study or analysis are self-service software, and what parts require Komodo services or a third-party analytics partner?
• Which outputs are appropriate for exploratory analytics, payer evidence, publication, trial planning, regulatory review, or commercial decisioning?
• How are Marmot or other AI-assisted results reviewed, versioned, cited, exported, and reproduced for audit or medical / legal review?
• What safeguards cover de-identification, tokenization, source rights, downstream sharing, and customer-provided data linkage?
• Which responsibilities does Komodo recommend using a specialist oncology, genomic, registry, EHR, or global data vendor instead?

Recent Activity

• 2026: Komodo’s public product taxonomy shifted toward Healthcare Map, Marmot, and Komodo Home as the three-layer platform packaging for life-sciences analytics.
• March 2026: ZERO Prostate Cancer and Komodo announced a partnership focused on identifying screening and care gaps.
• January 2026: GeneDx and Komodo announced a rare-disease data collaboration linking clinical and genomic context.
• 2025: Komodo launched Marmot as a healthcare-native AI analytics engine for faster cohort and evidence workflows.
• 2025: Helix and Komodo announced a clinico-genomic data partnership, adding whole-exome and clinical context to Healthcare Map use cases.
• 2024: Janssen R&D and Komodo published peer-reviewed validation work on clinical trial site selection using Healthcare Map-derived features.